841 related articles for article (PubMed ID: 31293582)
1. Pemphigus: Current and Future Therapeutic Strategies.
Didona D; Maglie R; Eming R; Hertl M
Front Immunol; 2019; 10():1418. PubMed ID: 31293582
[TBL] [Abstract][Full Text] [Related]
2. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.
Pollmann R; Schmidt T; Eming R; Hertl M
Clin Rev Allergy Immunol; 2018 Feb; 54(1):1-25. PubMed ID: 29313220
[TBL] [Abstract][Full Text] [Related]
3. Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice.
Hofrichter M; Dworschak J; Emtenani S; Langenhan J; Weiß F; Komorowski L; Zillikens D; Stöcker W; Probst C; Schmidt E; Goletz S
Front Immunol; 2018; 9():1935. PubMed ID: 30233569
[TBL] [Abstract][Full Text] [Related]
4. Pemphigus.
Kasperkiewicz M; Ellebrecht CT; Takahashi H; Yamagami J; Zillikens D; Payne AS; Amagai M
Nat Rev Dis Primers; 2017 May; 3():17026. PubMed ID: 28492232
[TBL] [Abstract][Full Text] [Related]
5. Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris.
Chen Y; Chernyavsky A; Webber RJ; Grando SA; Wang PH
J Biol Chem; 2015 Sep; 290(39):23826-37. PubMed ID: 26260795
[TBL] [Abstract][Full Text] [Related]
6. Pemphigus.
Schmidt E; Kasperkiewicz M; Joly P
Lancet; 2019 Sep; 394(10201):882-894. PubMed ID: 31498102
[TBL] [Abstract][Full Text] [Related]
7. Synergy among non-desmoglein antibodies contributes to the immunopathology of desmoglein antibody-negative pemphigus vulgaris.
Chernyavsky A; Amber KT; Agnoletti AF; Wang C; Grando SA
J Biol Chem; 2019 Mar; 294(12):4520-4528. PubMed ID: 30692201
[TBL] [Abstract][Full Text] [Related]
8. Pemphigus IgG causes skin splitting in the presence of both desmoglein 1 and desmoglein 3.
Spindler V; Drenckhahn D; Zillikens D; Waschke J
Am J Pathol; 2007 Sep; 171(3):906-16. PubMed ID: 17640963
[TBL] [Abstract][Full Text] [Related]
9. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.
Femiano F
Minerva Stomatol; 2007 Apr; 56(4):215-23. PubMed ID: 17452959
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions.
Nguyen VT; Ndoye A; Shultz LD; Pittelkow MR; Grando SA
J Clin Invest; 2000 Dec; 106(12):1467-79. PubMed ID: 11120754
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of synergy of autoantibodies to M3 muscarinic acetylcholine receptor and secretory pathway Ca
Chernyavsky A; Patel KG; Grando SA
Int Immunopharmacol; 2020 Mar; 80():106149. PubMed ID: 31958740
[TBL] [Abstract][Full Text] [Related]
12. Role of ADAM10 and ADAM17 in the Regulation of Keratinocyte Adhesion in Pemphigus Vulgaris.
Kugelmann D; Anders M; Sigmund AM; Egu DT; Eichkorn RA; Yazdi AS; Sárdy M; Hertl M; Didona D; Hashimoto T; Waschke J
Front Immunol; 2022; 13():884248. PubMed ID: 35844545
[TBL] [Abstract][Full Text] [Related]
13. Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.
Hébert V; Petit M; Maho-Vaillant M; Golinski ML; Riou G; Derambure C; Boyer O; Joly P; Calbo S
Front Immunol; 2019; 10():1794. PubMed ID: 31440235
[TBL] [Abstract][Full Text] [Related]
14. Pemphigus foliaceus.
Dasher D; Rubenstein D; Diaz LA
Curr Dir Autoimmun; 2008; 10():182-94. PubMed ID: 18460886
[TBL] [Abstract][Full Text] [Related]
15. Pemphigus vulgaris IgG directly inhibit desmoglein 3-mediated transinteraction.
Heupel WM; Zillikens D; Drenckhahn D; Waschke J
J Immunol; 2008 Aug; 181(3):1825-34. PubMed ID: 18641320
[TBL] [Abstract][Full Text] [Related]
16. Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
Maho-Vaillant M; Perals C; Golinski ML; Hébert V; Caillot F; Mignard C; Riou G; Petit M; Viguier M; Hertl M; Boyer O; Calbo S; Fazilleau N; Joly P
J Invest Dermatol; 2021 Sep; 141(9):2132-2140.e1. PubMed ID: 33766510
[TBL] [Abstract][Full Text] [Related]
17. Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab.
Bhatia SM; Streilein RD; Hall RP
PLoS One; 2020; 15(6):e0233957. PubMed ID: 32555697
[TBL] [Abstract][Full Text] [Related]
18. Keratin Retraction and Desmoglein3 Internalization Independently Contribute to Autoantibody-Induced Cell Dissociation in Pemphigus Vulgaris.
Schlögl E; Radeva MY; Vielmuth F; Schinner C; Waschke J; Spindler V
Front Immunol; 2018; 9():858. PubMed ID: 29922278
[No Abstract] [Full Text] [Related]
19. Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens.
Chernyavsky AI; Arredondo J; Kitajima Y; Sato-Nagai M; Grando SA
J Biol Chem; 2007 May; 282(18):13804-12. PubMed ID: 17344213
[TBL] [Abstract][Full Text] [Related]
20. The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus.
Vu TN; Lee TX; Ndoye A; Shultz LD; Pittelkow MR; Dahl MV; Lynch PJ; Grando SA
Arch Dermatol; 1998 Aug; 134(8):971-80. PubMed ID: 9722727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
